NCT00174902

Brief Summary

This randomized double-blinded controlled trial uses a factorial design to investigate whether application of beta-blockers (inderal 80 mg) or aspirin (100 mg) or a combination thereof has an effect on the activation of the hemostatic system, the platelets and the endothelium in response to acute mental stress. Specifically we test the hypothesis that inderal attenuates the activation of the hemostatic system as compared to placebo. The second hypothesis is that aspirin attenuates the activation of platelets as compared to placebo. Subjects will be randomly allocated to either of the four following study arms: placebo - inderal - aspirin - inderal plus aspirin. Subjects will receive the study medication for five days prior to the mental stress. The acute mental stress consists of a public speaking session of 10 min duration immediately followed by a mental arithmetic test of 5 min duration. Blood will be collected prior to the stress, immediately thereafter, at 45 min at at 1 hour and 45 min.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Oct 2003

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2003

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2004

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

September 9, 2005

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 15, 2005

Completed
Last Updated

October 25, 2006

Status Verified

October 1, 2003

First QC Date

September 9, 2005

Last Update Submit

October 24, 2006

Conditions

Keywords

Randomized controlled trialBlood plateletsHemostasisStress, psychologicalAdrenergic beta-antagonistsAspirinEndotheliumArteriosclerosis

Outcome Measures

Primary Outcomes (1)

  • Change scores in plasma levels of D-dimer determined by subtracting levels immediately after the stressor as compared to baseline levels prior to the stressor.

Secondary Outcomes (4)

  • Change scores of a) monocyte and T-lymphocyte expression of L-selectin, lymphocyte-function associated antigen (LFA-1), and CD40L

  • monocyte tissue-factor antigen (CD 142) expression

  • plasma levels of TAT, t-PA, and PAI-1

  • plasma levels of soluble intercellular adhesion molecule (sICAM-1), soluble vascular adhesion molecule (sVCAM-1), endothelin-1, and vWF

Interventions

Eligibility Criteria

Age40 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Life-time non-smoker or non-smoker for more than a year,
  • native language Swiss-German,
  • systolic blood pressure \<160 mm Hg, diastolic blood pressure \<100 mm Hg.
  • Subjects must have a body mass index that is not considered to be a cardiovascular risk factor, i.e. ≤ 26.5 kg/m2.

You may not qualify if:

  • Individuals reporting cardiovascular disease, renal disorders, endocrine disorders, hepatopathy, psychiatric disorders or who take regular medication for any of these conditions.
  • Persons are excluded, who report to drink \>5 cups (0.15 l each) of brewed coffee (\> 500 mg caffeine) a day, or who report drink more than 1.0 l beer and 0.45 l wine per day, respectively.
  • All subjects on regular beta-blocking or aspirin medication are excluded from the study.
  • Participants will be required not to take aspirin or any other non-steroidal anti-inflammatory drug during the study period, beginning 10 days prior to the first study medication.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Behavioral Sciences, Swiss Federal Institute of Technology

Zurich, CH-8092, Switzerland

Location

Related Publications (4)

  • von Kanel R, Mills PJ, Ziegler MG, Dimsdale JE. Effect of beta2-adrenergic receptor functioning and increased norepinephrine on the hypercoagulable state with mental stress. Am Heart J. 2002 Jul;144(1):68-72. doi: 10.1067/mhj.2002.123146.

    PMID: 12094190BACKGROUND
  • Mischler K, Fischer JE, Zgraggen L, Kudielka BM, Preckel D, von Kanel R. The effect of repeated acute mental stress on habituation and recovery responses in hemoconcentration and blood cells in healthy men. Life Sci. 2005 Jul 22;77(10):1166-79. doi: 10.1016/j.lfs.2005.03.006. Epub 2005 Apr 26.

  • von Kanel R, Kudielka BM, Preckel D, Hanebuth D, Fischer JE. Delayed response and lack of habituation in plasma interleukin-6 to acute mental stress in men. Brain Behav Immun. 2006 Jan;20(1):40-8. doi: 10.1016/j.bbi.2005.03.013.

  • von Kanel R, Preckel D, Zgraggen L, Mischler K, Kudielka BM, Haeberli A, Fischer JE. The effect of natural habituation on coagulation responses to acute mental stress and recovery in men. Thromb Haemost. 2004 Dec;92(6):1327-35. doi: 10.1160/TH04-04-0223.

MeSH Terms

Conditions

ArteriosclerosisStress, Psychological

Interventions

PropranololPharmaceutical PreparationsAspirin

Condition Hierarchy (Ancestors)

Arterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesBehavioral SymptomsBehavior

Intervention Hierarchy (Ancestors)

PhenoxypropanolaminesPropanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsPropanolsAminesNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPolycyclic CompoundsSalicylatesHydroxybenzoatesPhenolsBenzene Derivatives

Study Officials

  • Joachim E Fischer, MD, MSc

    Swiss Federal Institute of Technology, Institute of Behavioral Sciences

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
PREVENTION
Intervention Model
FACTORIAL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 9, 2005

First Posted

September 15, 2005

Study Start

October 1, 2003

Study Completion

August 1, 2004

Last Updated

October 25, 2006

Record last verified: 2003-10

Locations